间变性淋巴瘤激酶
医学
肺癌
克里唑蒂尼
靶向治疗
肿瘤科
内科学
癌症研究
临床试验
非小细胞肺癌
癌症
A549电池
恶性胸腔积液
作者
Jeffrey S. Ross,Siraj M. Ali,Omotayo Fasan,Jared Block,Sumanta K. Pal,Julia A. Elvin,Alexa B. Schrock,James Suh,Sahar Nozad,Sungeun Kim,Hwa Jeong Lee,Christine E. Sheehan,David Jones,Jo‐Anne Vergilio,Shakti Ramkissoon,Eric Severson,Sugganth Daniel,David Fabrizio,Garrett M. Frampton,V. A. Miller,Philip J. Stephens
出处
期刊:Oncologist
[Wiley]
日期:2017-12-01
卷期号:22 (12): 1444-1450
被引量:84
标识
DOI:10.1634/theoncologist.2016-0488
摘要
Abstract Background Genomic fusions of the anaplastic lymphoma kinase gene (ALK) are a well-established therapy target in non-small cell lung cancer (NSCLC). From a survey of 114,200 clinical cases, we determined the prevalence of ALK rearrangements (rALK) in non-NSCLC tumors and report their responsiveness to therapies targeting ALK. Materials and Methods Comprehensive genomic profiling of 114,200 relapsed and metastatic malignancies, including both solid tumors and hematolymphoid cancers, was performed using a hybrid-capture, adaptor ligation-based next-generation sequencing assay. Results Of 114,200 clinical samples, 21,522 (18.8%) were NSCLC and 92,678 (81.2%) were other tumor types. Of the 876 (0.8%) cases with ALK fusions (fALK) or rALK, 675 (77.1%) were NSCLC and 201 (22.9%) were other tumor types. ALK fusions were significantly more frequent in NSCLC (3.1%) than non-NSCLC (0.2%; p < .0001). Patients with non-NSCLC tumors harboring fALK were significantly younger (p < .0001) and more often female (p < .0001) than patients with fALK-positive NSCLC. EML4 was more often the fusion partner in NSCLC (83.5%) versus non-NSCLC tumors (30.9%; p < .0001). Conclusion ALK rearrangements can be identified in a wide variety of epithelial and mesenchymal malignancies beyond NSCLC. Anti-ALK therapies can be effective in non-NSCLC tumors driven by fALK, and further study of therapies targeting ALK in clinical trials involving a wider variety of cancer types appears warranted.
科研通智能强力驱动
Strongly Powered by AbleSci AI